financetom
Business
financetom
/
Business
/
Carvana Stock Is Moving Higher Thursday: What's Going On?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Carvana Stock Is Moving Higher Thursday: What's Going On?
May 26, 2025 4:18 AM

Carvana Co. ( CVNA ) shares are trading higher Thursday after the company reported better-than-expected first-quarter earnings on Wednesday after the market closed.

The Details: Carvana ( CVNA ) reported earnings per share of $1.51, beating the consensus estimate of 60 cents. Furthermore, the company reported sales of $4.23 billion, beating the consensus estimate of $3.98 billion and representing a 38% year-over-year climb.

Carvana ( CVNA ) reported it sold 133,898 retail units, representing a 46% year-over-year increase. The company announced its next management objective is to sell 3 million retail units per year at an Adjusted EBITDA margin of 13.5% within the next 5 to 10 years.

“In Q1, Carvana ( CVNA ) set a new record for retail units while also driving record profitability and hitting our highest customer net promoter score in nearly three years,” said Ernie Garcia, Carvana ( CVNA ) founder and CEO.

“We are incredibly well positioned for the path ahead and have very clear visibility to even stronger financial performance, much larger scales, and even better customer experiences. As Carvana ( CVNA ) grows larger and more efficient, we look forward to making our offering even faster and more convenient, and sharing the value we create with our customers as we continue our mission of changing the way people buy and sell cars.”

Analyst Changes: Following the earnings report, several analysts issued price target adjustments.

Wells Fargo analyst David Lantz maintained an Overweight rating on Carvana ( CVNA ) and raised the price target from $290 to $310.

Baird analyst Colin Sebastian maintained a Neutral rating on Carvana ( CVNA ) and raised the price target from $200 to $275.

Related Link: MSTR Stock Climbs Over 5% In Thursday Pre-Market: What’s Going On?

CVNA Price Action: At the time of writing, Carvana ( CVNA ) stock is trading 9.44% higher at $283.63, according to data from Benzinga Pro.

Image: via Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Salesforce Insider Sold Shares Worth $2,533,877, According to a Recent SEC Filing
Salesforce Insider Sold Shares Worth $2,533,877, According to a Recent SEC Filing
Oct 3, 2024
04:53 PM EDT, 09/27/2024 (MT Newswires) -- Maynard G Webb Jr, Director, on September 26, 2024, sold 9,170 shares in Salesforce ( CRM ) for $2,533,877. Following the Form 4 filing with the SEC, Webb has control over a total of 1,550 shares of the company, with 1,363 shares held directly and 187 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1108524/000112760224024543/xslF345X05/form4.xml Price: 276.59,...
Market Chatter: Banco Santander Hedged Equity Stake in Credit Agricole Joint Venture
Market Chatter: Banco Santander Hedged Equity Stake in Credit Agricole Joint Venture
Oct 3, 2024
04:57 PM EDT, 09/27/2024 (MT Newswires) -- Banco Santander (SAN) hedged its equity stake in CACEIS, a joint venture with Credit Agricole, to reduce its regulatory burden, Bloomberg News reported Friday, citing people with knowledge of the matter. The hedge involved a type of put option to offload risk from the 30.5% stake with at least some going to D.E....
Poseida Therapeutics Study of Prospective Myeloma Treatment Yields Positive Data
Poseida Therapeutics Study of Prospective Myeloma Treatment Yields Positive Data
Oct 3, 2024
04:56 PM EDT, 09/27/2024 (MT Newswires) -- Poseida Therapeutics ( PSTX ) said late Friday a phase 1 trial of P-BCMA-ALLO1 therapy to treat relapsed or refractory multiple myeloma, a type of cancer, yielded positive data. The company said data showed an overall response rate of 91% and compelling safety results in the 23 heavily pretreated patients in an optimized...
BRIEF-Jacobs Advances Strategic Transformation With Completion Of Previously Announced Spin-Off And Merger
BRIEF-Jacobs Advances Strategic Transformation With Completion Of Previously Announced Spin-Off And Merger
Oct 3, 2024
Sept 27 (Reuters) - Jacobs Solutions Inc ( J ): * JACOBS ADVANCES STRATEGIC TRANSFORMATION WITH COMPLETION OF PREVIOUSLY ANNOUNCED SPIN-OFF AND MERGER Source text for Eikon: Further company coverage: ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved